Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Cancer-immune checkpoint inhibition and autoimmune-related adverse events.
Authors
Joerg Rathmann
St Francis Care Reg Cancer Ctr, Hartford, CT
Joerg Rathmann, James J. Vredenburgh, Racha Demesropian, Dorothy Wakefield, Kendra Williams, Archana Purushothaman, Jessica Bello, Latha Dulipsingh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 107)
DOI
10.1200/JCO.2019.37.8_suppl.107
Abstract #
107
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.
First Author: Anthony B. El-Khoueiry
Poster
2019 ASCO Annual Meeting
A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).
First Author: Julio Antonio Peguero
Poster
2019 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.
First Author: Andreas Nicholas Saltos
Poster
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
First Author: Saveri Bhattacharya